{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual titer value for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG001","title":"2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab"},{"description":"Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.","id":"OG002","title":"2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab"}],"paramType":"MEDIAN","populationDescription":"Safety population. Only those participants with positive post-baseline antibody against belantamab mafodotin were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 281 weeks","title":"DE Phase: Titer of ADAs Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"Titer"}